CIPLA vs SUNPHARMA
Side-by-side comparison of Cipla Ltd. and Sun Pharmaceutical Industries Ltd.. Descriptive only — not investment advice.
Cipla Ltd.
Pharma
Quality Score: 51/100
Sun Pharmaceutical Industries Ltd.
Pharma
Quality Score: 73/100
At a glance
| Metric | CIPLA | SUNPHARMA |
|---|---|---|
| Quality Score | 51/100 | 73/100 |
| P/E (trailing) | 35.1 | 38.6 |
| Forward P/E | 23.0 | 29.6 |
| ROE | — | — |
| Profit margin | +12.0% | +20.2% |
| Debt-to-equity | 1.78 | 5.52 |
| Dividend yield | +0.89% | +0.82% |
| 1Y price return | -1.0% | +20.3% |
| From 52w high | -11.7% | -5.0% |
| Analyst rating1 = Strong Buy, 5 = Strong Sell | 2.19 | 1.76 |
Highlighted value = better on the metric (lower for P/E, D/E, drawdown, analyst rating; higher elsewhere). Descriptive only.
Snapshots
Cipla trades at Rs 1,463, up 3.12% over the trailing 3 months but down 0.96% over the trailing 1 year, sitting 11.73% below its 52-week high while holding above both the 50-DMA (Rs 1,426.93) and 200-DMA (Rs 1,391.53). Q1 FY27 net profit was reported down about 39% YoY on weaker North America sales, in line with 5-year earnings growth of -39.2%, even as the trailing PE of 35.10 compresses to a forward PE of 23.05.
Sun Pharma trades at Rs 1,945, up 20.26% over the past year and 6.87% over three months, sitting 4.98% below its 52-week high and above both its 50-day (1,885.96) and 200-day (1,775.23) moving averages, with RSI at a neutral 52.1. Q1 FY27 profit rose 27% year-over-year to Rs 2,894 crore on 10.5% revenue growth, alongside continued progress on the proposed Organon merger, which cleared Organon shareholder approval on July 24, 2026. Trailing PE is 38.6x (forward 29.6x) against a Pharma peer set spanning 29.5x (Dr. Reddy's) to 85.5x (Divi's Labs).
Pros
- ✓Debt-to-equity of roughly 0.02x (raw metric 1.78, percent-scaled) with a 'falling' debt trend per the persistence data and free cash flow positive in 4 of the last 5 tracked years.
- ✓Forward PE of 23.05 compares to a trailing PE of 35.10, a roughly 34% compression.
- ✓Mean analyst rating of 2.19 across 36 analysts (1-5 scale, lower = more constructive).
- ✓Price trades above both the 50-DMA (Rs 1,426.93) and 200-DMA (Rs 1,391.53), with RSI at a neutral 55.74, and trailing PE ranks 2nd-lowest among 6 tracked Pharma peers.
- ✓Price sits above both the 50-day (1,885.96) and 200-day (1,775.23) simple moving averages, up 20.26% over 12 months and 6.87% over 3 months, only 4.98% below its 52-week high.
- ✓Q1 FY27 net profit rose 27% year-over-year to Rs 2,894 crore, with a 20.19% profit margin and 10.5% revenue growth.
- ✓Free cash flow was positive in 4 of the tracked years, debt trend is described as falling, and the quality score of 57 ranks 1st of 6 among the Pharma peers tracked.
- ✓Mean analyst rating of 1.76 across 33 analysts (1-5 scale, lower = more constructive); 7 of the 8 most recent news items carry positive sentiment.
Cons
- ✗5-year earnings growth of -39.2%, echoed in Q1 FY27 net profit reported down about 39% YoY to roughly Rs 785-789 crore on weaker North America sales.
- ✗ROE exceeded 15% in only 2 of the last 5 tracked years; profit margin stands at 12.01%.
- ✗Quality score of 28 ranks 5th of 6 tracked Pharma peers; 5-year revenue growth has been muted at 3.5%.
- ✗News sentiment across 8 tracked items skews negative (5 negative, 2 positive, 1 neutral), concentrated around the Q1 FY27 results.
- ✗Current-period ROE is not reported; only 3 of the tracked years show ROE above 15% (consistency score 73/100), a softer read than the 27.4% five-year earnings growth alone would suggest.
- ✗A Moneycontrol report on the July 31, 2026 Q1 print described revenue and profit as coming in below analyst estimates, even as the same quarter's 27% year-over-year profit growth was reported positively elsewhere.
- ✗The proposed Organon merger cleared shareholder approval on July 24, 2026, but deal financing structure, closing timeline and integration detail are not present in the available data.
- ✗Trailing PE of 38.6x sits above 3 of the 5 tracked Pharma peers (Dr. Reddy's 29.5x, Cipla 35.1x, Apollo Hospitals 66.2x), though below Max Healthcare (72.4x) and Divi's Labs (85.5x).
Want the full analysis for either stock?
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Comparison reflects current public data; consult a registered adviser before any investment decision.